Improving patients' lives through better healthcare begins with a commitment to innovation. Our research and development pipeline is where we put that commitment to work. Takeda Global Research & Development Center, Inc. dedicates its resources to the Takeda product pipeline in an effort to improve people’s lives. As a research-based pharmaceutical company efforts are currently focused on preclinical work and clinical development activities.
| Compound |
Therapeutic Area |
Stage |
| alogliptin |
Diabetes mellitus |
NDA submitted |
| dexlansoprazole |
Gastroenterology |
NDA submitted |
| febuxostat |
Rheumatology |
NDA submitted |
| TAK-491 |
Hypertension |
Phase 3 |
| hematide |
Chronic kidney disease (CKD) |
Phase 3 |
| L21004 MDD |
Depression/anxiety |
Phase 3 |
| SYR-322-4833 |
Diabetes Type 2 |
Phase 3 |
| TAK-242 |
Sepsis |
Phase 3 |
| MLNM002 |
Crohn’s and Ulcerative Colitis |
Phase 3 |